<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370043</url>
  </required_header>
  <id_info>
    <org_study_id>KQ-791-01</org_study_id>
    <nct_id>NCT02370043</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of KQ-791 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaneq Bioscience Limited</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaneq Bioscience Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and the effect of food on
      KQ-791. Each participant may receive up to 3 single doses of KQ-791 (at up to 3 different
      dose levels) and 1 placebo dose over the course of the study. Up to 6 escalating dose levels
      may be studied, in two distinct groups or cohorts.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2015</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug</measure>
    <time_frame>Baseline to study completion (up to 11 weeks)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, and 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg'</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Residual Area</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
    <description>calculated as 100*(1- AUC0-t / AUC0-inf)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Observed Cmax (Tmax)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Half-Life (T1/2 el)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (Kel)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Body Clearance (Cl/F)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (Vd/F)</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) in Fed Versus Fasting State</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) in Fed Versus Fasting State</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Drug Concentration (Cmax) in Fed Versus Fasting State</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Drug Concentration (Tmax) in Fed Versus Fasting State</measure>
    <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Drug Excreted in Urine</measure>
    <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t)</measure>
    <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Rate of Urinary Excretion (Rmax)</measure>
    <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Rmax Urinary Excretion (TRmax)</measure>
    <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Clearance (Clr)</measure>
    <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
    <description>Calculated by the following equation: Ae0-t/AUC0-24</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>KQ-791</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of KQ-791, starting at 15 milligrams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KQ-791 (after meal)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of KQ-791 in capsule form, after a meal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of placebo matching KQ-791 dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KQ-791</intervention_name>
    <description>Capsules administered orally while fasting, in up to 3 periods</description>
    <arm_group_label>KQ-791</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KQ-791 (after meal)</intervention_name>
    <description>Single dose of KQ-791 in capsules, after a meal, in 1 period</description>
    <arm_group_label>KQ-791 (after meal)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsules, administered orally, in 1 period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or non-childbearing potential female, which includes post-menopausal female
             (absence of menses for 12 months prior to drug administration, bilateral oophorectomy
             or hysterectomy with bilateral oophorectomy at least 6 months prior to drug
             administration) or surgically sterile female (hysterectomy or tubal ligation at least
             6 months prior to drug administration)

          -  Body Mass Index (BMI) greater than or equal to (≥) 27.0 and less than or equal to (≤)
             35.0 kilogram per square meter (kg/m2)

          -  Healthy as defined by:

               1. absence of clinically significant illness and surgery within last 4 weeks.
                  Participants vomiting within 24 hours pre-dose will be evaluated for upcoming
                  illness/disease

               2. the absence of clinically significant history of neurological, endocrine,
                  cardiovascular, pulmonary, hematological, immunologic, psychiatric,
                  gastrointestinal, renal, hepatic, or metabolic disease

          -  Male participants who are not vasectomized for at least 6 months, and who are sexually
             active with non-sterile female partner (sterile female partners include
             post-menopausal females and surgically sterile females) must be willing to use one of
             the following acceptable contraceptive methods throughout the study and for 90 days
             after the last study drug administration:

               1. simultaneous use of a condom, and for the female partner hormonal contraceptives
                  (used since at least 4 weeks) or intra-uterine contraceptive device (placed since
                  at least 4 weeks)

               2. simultaneous use of a male condom, and for his female partner, a diaphragm with
                  intravaginally applied spermicide

          -  Some degree of insulin resistance, as shown by:

               1. fasting blood glucose ≥95.4 and ≤126 milligrams per deciliter (mg/dL) (equivalent
                  to 5.3 to 7.0 millimoles per liter (mmol/L), respectively) and

               2. fasting triglycerides ≤ 4.0 mmol/L, and/or

               3. Low-Density Lipoprotein Cholesterol (LDL-C) ≤ 6.0 mmol/L

          -  Capable of consent

          -  Non-smoker (no use of tobacco products within the last 3 months)

        Exclusion Criteria:

          -  Any clinically significant abnormality or abnormal laboratory test results (other than
             glucose,triglycerides and LDL-C levels described in inclusion criterion)

          -  Positive test for hepatitis B, hepatitis C, or Human Immunodeficiency Virus (HIV)

          -  Evidence of clinically significant hepatic or renal impairment, including Alanine
             Aminotransferase (ALT) above 1.5x Upper Limit of Normal (ULN), Aspartate
             Aminotransferase (AST) above 2x ULN, total bilirubin above 2x ULN (total bilirubin
             accepted up to 2x ULN if direct bilirubin is within normal limits), or Estimated
             Glomerular Filtration Rate (eGFR) less than (&lt;) 90 milliliters per minute (mL/minute)

          -  Positive urine drug screen

          -  History of significant allergic reactions (e.g. angioedema) to any drug.

          -  Use of any drugs known to induce or inhibit hepatic drug metabolism within the last 30
             days

          -  Positive pregnancy test

          -  Any reason which, in the opinion of the qualified investigator (QI) would prevent the
             subject from participating in the study

          -  Clinically significant electrocardiogram (ECG) abnormalities at screening, or
             clinically significant personal or family history (in a first-degree relative) of
             heart diseases, including:

               1. Confirmed corrected QT (QTcF) interval greater than (&gt;) 450 milliseconds (msec)
                  for men and women

               2. Bundle branch blocks and other conduction abnormalities other than mild first
                  degree atrio-ventricular block

               3. Irregular rhythms other than sinus arrhythmia or occasional, rare
                  supraventricular ectopic beats

          -  History of unexplained syncope

          -  Family history of unexplained sudden death or sudden death due to long QT syndrome

          -  T-wave configurations are not of sufficient quality for assessing QT interval

          -  Clinically significant vital sign abnormalities (systolic blood pressure lower than 90
             or over 150 mmHg, diastolic blood pressure lower than 50 or over 95 mmHg, or heart
             rate less than 50 or over 100 beats per minute (bpm))

          -  History of significant alcohol abuse within one year prior to screening or regular use
             of alcohol within six months prior to the screening (regular use of more than three
             units of alcohol per day for males and more than two units of alcohol per day for
             females [1 unit = 150 (milliliter) mL of wine, 360 mL of beer, or 45 mL of 40%
             alcohol]) or positive alcohol breath test

          -  History of significant drug abuse within the last year or use of soft drugs (such as
             marijuana) within 3 months prior, or hard drugs (such as cocaine, phencyclidine (PCP)
             and crack) within the last year

          -  Participation in a clinical trial involving the administration of an investigational
             or marketed drug within the last 30 days (90 days for biologics) or concomitant
             participation in an investigational study

          -  Use of medication other than topical products without significant systemic absorption:

               1. prescription medication within last 14 days

               2. over-the-counter products within the last 7 days, with the exception of the
                  occasional use of acetaminophen (up to 2 grams (g) daily)

               3. natural health products (e.g. food supplements or herbal supplements) within last
                  14 days

               4. a depot injection or an implant of any drug within last 3 months

          -  Donation of plasma within the last 7 days. Donation or loss of blood of 50 mL to 499
             mL of blood within 30 days, or more than 499 mL within 56 days

          -  Hemoglobin &lt;128 grams per liter (g/L) (males) and &lt;115 g/L (females) and hematocrit
             &lt;0.37 L/L (males) and &lt;0.32 L/L (females)

          -  Breast-feeding participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email: daniel.bouthillier@Kaneq.ca</last_name>
    <role>Study Director</role>
    <affiliation>Kaneq Bioscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Inventiv</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3X 2Hp</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>inVentiv</name>
      <address>
        <city>Quebec</city>
        <zip>G1P 0A2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>February 18, 2015</study_first_submitted>
  <study_first_submitted_qc>February 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2015</study_first_posted>
  <results_first_submitted>February 28, 2017</results_first_submitted>
  <results_first_submitted_qc>October 7, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 30, 2019</results_first_posted>
  <last_update_submitted>November 14, 2019</last_update_submitted>
  <last_update_submitted_qc>November 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Sequence 60 mg/600 mg/Placebo subject discontinued after completion of 600 mg. Sequence Placebo/600 mg/1800 mg subject discontinued after completion of placebo.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence: 15 mg/Placebo/1200 mg/Placebo (Fed)</title>
        </group>
        <group group_id="P2">
          <title>Sequence: 15 mg KQ791/195 mg/Placebo/195 mg (Fed)</title>
        </group>
        <group group_id="P3">
          <title>Sequence: Placebo/195 mg/1200 mg/195 mg (Fed)</title>
        </group>
        <group group_id="P4">
          <title>Sequence: 60 mg/Placebo/1800 mg</title>
        </group>
        <group group_id="P5">
          <title>Sequence: 60 mg/600 mg/Placebo</title>
        </group>
        <group group_id="P6">
          <title>Sequence: Placebo/600 mg/1800 mg</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug</title>
        <time_frame>Baseline to study completion (up to 11 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
          <group group_id="O8">
            <title>Placebo (Fed)</title>
          </group>
          <group group_id="O9">
            <title>Placebo (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious Adverse Events (SAEs) Considered by the Investigator to be Related to Study Drug</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-t.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-t.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34699.23" spread="44.87"/>
                    <measurement group_id="O2" value="95223.95" spread="32.54"/>
                    <measurement group_id="O3" value="358380.52" spread="36.34"/>
                    <measurement group_id="O4" value="110566.98" spread="17.39"/>
                    <measurement group_id="O5" value="721393.21" spread="32.49"/>
                    <measurement group_id="O6" value="1207610.37" spread="29.83"/>
                    <measurement group_id="O7" value="2137673.75" spread="34.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, and 24 hours post-dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-24.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero to 24-hour Post-Dose (AUC0-24)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-24.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3410.02" spread="55.50"/>
                    <measurement group_id="O2" value="12251.48" spread="25.11"/>
                    <measurement group_id="O3" value="33151.96" spread="34.63"/>
                    <measurement group_id="O4" value="16718.65" spread="17.76"/>
                    <measurement group_id="O5" value="60448.26" spread="46.92"/>
                    <measurement group_id="O6" value="113891.92" spread="24.54"/>
                    <measurement group_id="O7" value="178100.82" spread="44.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg'</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-inf.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC0-inf)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-inf.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40581.44" spread="51.90"/>
                    <measurement group_id="O2" value="128600.49" spread="37.47"/>
                    <measurement group_id="O3" value="387934.16" spread="31.98"/>
                    <measurement group_id="O4" value="120230.35" spread="9.81"/>
                    <measurement group_id="O5" value="776014.78" spread="37.64"/>
                    <measurement group_id="O6" value="1311488.40" spread="29.23"/>
                    <measurement group_id="O7" value="2176168.42" spread="34.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Cmax.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.65" spread="65.96"/>
                    <measurement group_id="O2" value="637.51" spread="29.32"/>
                    <measurement group_id="O3" value="1857.08" spread="45.29"/>
                    <measurement group_id="O4" value="923.51" spread="20.32"/>
                    <measurement group_id="O5" value="3238.86" spread="52.73"/>
                    <measurement group_id="O6" value="5828.97" spread="32.07"/>
                    <measurement group_id="O7" value="9418.01" spread="44.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Residual Area</title>
        <description>calculated as 100*(1- AUC0-t / AUC0-inf)</description>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Residual Area.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Residual Area</title>
          <description>calculated as 100*(1- AUC0-t / AUC0-inf)</description>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Residual Area.</population>
          <units>Percentage residual area under the AUC</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.59" spread="107.28"/>
                    <measurement group_id="O2" value="11.51" spread="45.28"/>
                    <measurement group_id="O3" value="3.58" spread="113.37"/>
                    <measurement group_id="O4" value="13.23" spread="50.26"/>
                    <measurement group_id="O5" value="4.25" spread="88.29"/>
                    <measurement group_id="O6" value="4.53" spread="84.07"/>
                    <measurement group_id="O7" value="1.55" spread="47.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Observed Cmax (Tmax)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Time to Observed Cmax (Tmax)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Tmax.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="2" upper_limit="7.99"/>
                    <measurement group_id="O2" value="5" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O3" value="4" lower_limit="3.99" upper_limit="48"/>
                    <measurement group_id="O4" value="8" lower_limit="6" upper_limit="10"/>
                    <measurement group_id="O5" value="5.01" lower_limit="4" upper_limit="8"/>
                    <measurement group_id="O6" value="8" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O7" value="7.06" lower_limit="4" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Half-Life (T1/2 el)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute T1/2 el.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Elimination Half-Life (T1/2 el)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute T1/2 el.</population>
          <units>Hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200.67" spread="16.89"/>
                    <measurement group_id="O2" value="196.45" spread="17.67"/>
                    <measurement group_id="O3" value="214.42" spread="28.77"/>
                    <measurement group_id="O4" value="76.86" spread="22.80"/>
                    <measurement group_id="O5" value="219.71" spread="7.83"/>
                    <measurement group_id="O6" value="197.77" spread="24.28"/>
                    <measurement group_id="O7" value="215.58" spread="12.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination Rate Constant (Kel)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Kel.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Elimination Rate Constant (Kel)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Kel.</population>
          <units>Per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0035" spread="18.9823"/>
                    <measurement group_id="O2" value="0.0035" spread="16.0482"/>
                    <measurement group_id="O3" value="0.0032" spread="32.1756"/>
                    <measurement group_id="O4" value="0.0090" spread="22.8030"/>
                    <measurement group_id="O5" value="0.0032" spread="7.9026"/>
                    <measurement group_id="O6" value="0.0035" spread="28.6322"/>
                    <measurement group_id="O7" value="0.0032" spread="14.2298"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Body Clearance (Cl/F)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute CI/F.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Body Clearance (Cl/F)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute CI/F.</population>
          <units>Liters per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3696" spread="48.4762"/>
                    <measurement group_id="O2" value="0.4666" spread="43.0267"/>
                    <measurement group_id="O3" value="0.5027" spread="32.8329"/>
                    <measurement group_id="O4" value="1.6219" spread="9.8091"/>
                    <measurement group_id="O5" value="0.7732" spread="47.0999"/>
                    <measurement group_id="O6" value="0.9150" spread="37.9245"/>
                    <measurement group_id="O7" value="0.8271" spread="40.4976"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution (Vd/F)</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Vd/F.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution (Vd/F)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Vd/F.</population>
          <units>Liters</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.01" spread="34.95"/>
                    <measurement group_id="O2" value="132.23" spread="32.37"/>
                    <measurement group_id="O3" value="155.49" spread="27.72"/>
                    <measurement group_id="O4" value="179.83" spread="13.14"/>
                    <measurement group_id="O5" value="245.08" spread="46.56"/>
                    <measurement group_id="O6" value="261.06" spread="18.01"/>
                    <measurement group_id="O7" value="257.25" spread="29.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) in Fed Versus Fasting State</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-inf in Fed versus Fasting State.</population>
        <group_list>
          <group group_id="O1">
            <title>195 mg KQ-791</title>
            <description>Food Effect (Fed/Fasting)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to Infinity (AUC0-inf) in Fed Versus Fasting State</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute AUC0-inf in Fed versus Fasting State.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="15.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) in Fed Versus Fasting State</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <group_list>
          <group group_id="O1">
            <title>195 mg KQ-791</title>
            <description>Food Effect (Fed/Fasting)</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Time Zero to the Last Non-Zero Concentration (AUC0-t) in Fed Versus Fasting State</title>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="37.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Observed Drug Concentration (Cmax) in Fed Versus Fasting State</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels, and on Day 28 for dose level 195 mg; on Days 14 and 28 for dose level 600 mg; and on Days 14, 28, and 56 for dose level 1800 mg</time_frame>
        <group_list>
          <group group_id="O1">
            <title>195 mg KQ-791</title>
            <description>Food Effect (Fed/Fasting)</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Observed Drug Concentration (Cmax) in Fed Versus Fasting State</title>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" spread="59.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Drug Concentration (Tmax) in Fed Versus Fasting State</title>
        <time_frame>Pre-dose and 0.5, 1, 2, 4, 6, 8,10, 24, 48, 96, and 144 hours post-dose, and on Day 10 for all dose levels</time_frame>
        <group_list>
          <group group_id="O1">
            <title>195 mg KQ-791</title>
            <description>Food Effect (Fed/Fasting)</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Drug Concentration (Tmax) in Fed Versus Fasting State</title>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="-40.01" upper_limit="5.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Drug Excreted in Urine</title>
        <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute the Amount of Drug Excreted in Urine.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
            <description>12-24 hours post-dose</description>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
            <description>12-24 hours post-dose</description>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
            <description>12-24 hours post-dose</description>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
            <description>12-24 hours post dose</description>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
            <description>12-24 hours post dose</description>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
            <description>12-24 hours post-dose</description>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
            <description>12-24 hours post-dose</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Drug Excreted in Urine</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute the Amount of Drug Excreted in Urine.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.72" spread="27.71"/>
                    <measurement group_id="O2" value="155.51" spread="15.81"/>
                    <measurement group_id="O3" value="381.35" spread="34.71"/>
                    <measurement group_id="O4" value="224.51" spread="31.25"/>
                    <measurement group_id="O5" value="739.07" spread="67.68"/>
                    <measurement group_id="O6" value="1796.43" spread="29.85"/>
                    <measurement group_id="O7" value="3069.11" spread="37.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t)</title>
        <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Ae0-t.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Urinary Excretion From Time Zero to Time t (Ae0-t)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Ae0-t.</population>
          <units>μg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.60" spread="37.17"/>
                    <measurement group_id="O2" value="350.68" spread="19.39"/>
                    <measurement group_id="O3" value="859.41" spread="39.32"/>
                    <measurement group_id="O4" value="421.70" spread="27.23"/>
                    <measurement group_id="O5" value="1893.11" spread="57.89"/>
                    <measurement group_id="O6" value="3793.47" spread="34.98"/>
                    <measurement group_id="O7" value="6680.04" spread="38.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Rate of Urinary Excretion (Rmax)</title>
        <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Rmax.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Maximum Rate of Urinary Excretion (Rmax)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Rmax.</population>
          <units>μg/hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.13" spread="44.88"/>
                    <measurement group_id="O2" value="21.09" spread="29.33"/>
                    <measurement group_id="O3" value="49.05" spread="39.75"/>
                    <measurement group_id="O4" value="25.53" spread="29.88"/>
                    <measurement group_id="O5" value="123.11" spread="48.42"/>
                    <measurement group_id="O6" value="206.83" spread="33.25"/>
                    <measurement group_id="O7" value="377.72" spread="38.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time of Rmax Urinary Excretion (TRmax)</title>
        <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute TRmax.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Time of Rmax Urinary Excretion (TRmax)</title>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute TRmax.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.93" lower_limit="5.91" upper_limit="5.94"/>
                    <measurement group_id="O2" value="5.93" lower_limit="5.90" upper_limit="9.91"/>
                    <measurement group_id="O3" value="5.91" lower_limit="5.87" upper_limit="9.90"/>
                    <measurement group_id="O4" value="9.88" lower_limit="5.85" upper_limit="9.91"/>
                    <measurement group_id="O5" value="5.88" lower_limit="5.86" upper_limit="5.90"/>
                    <measurement group_id="O6" value="9.90" lower_limit="5.84" upper_limit="9.96"/>
                    <measurement group_id="O7" value="5.96" lower_limit="5.89" upper_limit="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Clearance (Clr)</title>
        <description>Calculated by the following equation: Ae0-t/AUC0-24</description>
        <time_frame>Four hour intervals up to 12 hours, and then 12-24 hours post dose</time_frame>
        <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Clr.</population>
        <group_list>
          <group group_id="O1">
            <title>15 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O2">
            <title>60 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O3">
            <title>195 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O4">
            <title>195 mg KQ-791 (Fed)</title>
          </group>
          <group group_id="O5">
            <title>600 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O6">
            <title>1200 mg KQ-791 (Fasting)</title>
          </group>
          <group group_id="O7">
            <title>1800 mg Kq-791 (Fasting)</title>
          </group>
        </group_list>
        <measure>
          <title>Renal Clearance (Clr)</title>
          <description>Calculated by the following equation: Ae0-t/AUC0-24</description>
          <population>All randomized participants who received at least 1 dose of KQ-791and had sufficient evaluable PK data to compute Clr.</population>
          <units>Liters per hour</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="6"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0266" spread="31.5426"/>
                    <measurement group_id="O2" value="0.0286" spread="19.7181"/>
                    <measurement group_id="O3" value="0.0259" spread="19.7678"/>
                    <measurement group_id="O4" value="0.0252" spread="20.7044"/>
                    <measurement group_id="O5" value="0.0313" spread="17.2647"/>
                    <measurement group_id="O6" value="0.0333" spread="18.6140"/>
                    <measurement group_id="O7" value="0.0375" spread="9.5596"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Collected at each visit</desc>
      <group_list>
        <group group_id="E1">
          <title>15 mg KQ-791 (Fasting)</title>
        </group>
        <group group_id="E2">
          <title>60 mg KQ-791 (Fasting)</title>
        </group>
        <group group_id="E3">
          <title>195 mg KQ-791 (Fasting)</title>
        </group>
        <group group_id="E4">
          <title>195 mg KQ-791 (Fed)</title>
        </group>
        <group group_id="E5">
          <title>600 mg KQ-791 (Fasting)</title>
        </group>
        <group group_id="E6">
          <title>1200 mg KQ-791 (Fasting)</title>
        </group>
        <group group_id="E7">
          <title>1800 mg Kq-791 (Fasting)</title>
        </group>
        <group group_id="E8">
          <title>Placebo (Fasting)</title>
        </group>
        <group group_id="E9">
          <title>Placebo (Fed)</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="17"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increases</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Faeces discolored</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastresophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Procedural dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood tryglycerides increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>High density lipoprotein decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Heart Rate Increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neck Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gosse Bruinsma</name_or_title>
      <organization>Kaneq Bioscience Limited</organization>
      <phone>1-613-800-0955</phone>
      <email>gosse.bruinsma@kaneqbioscience.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

